NCT06279130 2026-03-05
NEOASIS
The Netherlands Cancer Institute
Phase 2/3 Recruiting
Clinical Trials
13 trialsNCT03686202 2026-02-09
MET4-IO
University Health Network, Toronto
Phase 2/3 Active not recruiting
NCT04353375 2025-12-31
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Hutchmed
Phase 2/3 Recruiting
NCT04681417 2025-11-28
RETINO 2018
Institut Curie
Phase 2/3 Recruiting
NCT02784171 2024-12-10
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2/3 Completed
NCT03610360 2024-02-01
DENIM
Amphera BV
Phase 2/3 Completed
NCT05955157 2024-01-10
Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma
University of Malaya
Phase 2/3 Unknown
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT00651456 2023-03-13
MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3 Completed
NCT02910726 2022-10-05
A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers
Memorial Sloan Kettering Cancer Center
Phase 2/3 Completed
NCT03975036 2019-06-05
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
Henan Cancer Hospital
Phase 2/3 Unknown
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated